by Gi Yeonjin
Published 25 Apr.2022 16:10(KST)
[Asia Economy Reporter Ji Yeon-jin] Samsung Biologics announced on the 25th that it has signed a letter of intent for a contract worth 154 billion KRW for contract manufacturing of biopharmaceuticals with a European pharmaceutical company. The contract period is from today until August 31.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.